Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus chemotherapy versus pembrolizumab plus chemotherapy in pMMR advanced or recurrent endometrial cancer
jRCT2031260572Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing PF-08634404 + standard-of-care chemotherapy with Keytruda + standard-of-care chemotherapy (2 arms). Primary endpoint: Progression-free survival by blinded independent central review. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PF-08634404pembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031260572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260572.